Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.
Company Details
- Employees
- 18
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.kynexistx.com
- Keywords
- MBrace Therapeutics.
Kynexis Questions
Kynexis's website is https://www.kynexistx.com
Kynexis's LinkedIn profile is https://www.linkedin.com/company/kynexis
Kynexis has
18 employees.
View email and phone details for 18
employees at Kynexis.
Kynexis's industry is
Biotechnology Research
Kynexis's top competitors are
Seamless Therapeutics,
Forbion,
Aro Biotherapeutics,
Vectory,
Orsobio,
2 Bridge,
T-Therapeutics Ltd,
Mbrace Therapeutics,
Gate Bioscience,
Tagworks Pharmaceuticals.
Kynexis's categories are Biotechnology Research
